Evidence map›Paper›PMID 40027147›Full record

ReviewThe journal of liquid biopsy2024

Putting comprehensive genomic profiling of ctDNA to work: 10 proposed use cases.

Aakash Desai, Lincoln W Pasquina, Candice Nulsen, Rachel B Keller-Evans, Douglas A Mata, Hanna Tukachinsky, Geoffrey R Oxnard

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The journal of liquid biopsy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Real-world adoption of off-label combinations for targeted therapy resistance in non-small cell lung cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Aakash DesaiDivision of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, AL, USA.
Lincoln W PasquinaFoundation Medicine, Inc., Boston, MA, USA.
Candice NulsenFoundation Medicine, Inc., Boston, MA, USA.
Rachel B Keller-EvansFoundation Medicine, Inc., Boston, MA, USA.
Douglas A MataFoundation Medicine, Inc., Boston, MA, USA.
Hanna TukachinskyFoundation Medicine, Inc., Boston, MA, USA.
Geoffrey R OxnardBoston Medical Center, Boston, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liquid biopsy profiling of circulating tumor DNA (ctDNA) has become established as a compelling, pragmatic diagnostic in the care of cancer patients and is now endorsed by multiple cancer care guidelines. Moreover, ctDNA profiling technologies have advanced significantly and offer increasingly comprehensive and reliable insights into cancer. In this review, we focus on applications of ctDNA and propose that a critical untapped opportunity is in considering how we utilize these accessible, scalable technologies across diverse potential applications. With a specific focus on clinical applications, rather than research uses, we describe 10 use cases for ctDNA profiling across four categories: (1) established and (2) emerging applications of ctDNA profiling for therapy selection, (3) incidental detection of secondary genomic findings, and (4) quantification of plasma DNA tumor content.

Indexed as

Circulating tumor DNAComprehensive genomic profilingLiquid biopsy

Identifiers

PMID40027147
PMCPMC11863816

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.